GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
GT Biopharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$6.69−0.34 (-4.84%)
Close on Oct 19, 2026
- Market cap
- $259.71M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns GT Biopharma's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Five Narrow Lane LP | 253,388 | 9.99% | 13G (passive) | May 13, 2025 |
| Cytovance Biologics Inc | 219,457 | 9.80% | 13G (passive) amendment | Sep 30, 2024 |
| RainForest Partners, LLC | 180,258 | 9.99% | 13G (passive) | Sep 15, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Martin Breen | CEO and Director | 856,218 | 1.90% | Sep 8, 2025 |
| Alan Louis Urban | Chief Financial Officer | – | – | Sep 8, 2025 |
| Charles J. Casamento | Director | – | – | Sep 8, 2025 |
| Hilary Kramer | Director | – | – | Sep 8, 2025 |
| David C. Mun-Gavin | Director | – | – | Sep 8, 2025 |
| Andrew J. Ritter | Director | – | – | May 29, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Manu Ohri CFO & Secretary | Aug 11, 2023 | Award | +200,000 | $0.29 | $58.00K | 200,000 |
| Manu Ohri CFO & Secretary | Aug 11, 2023 | Other | −200,000 | $0.29 | $58.00K | 0 |
| Manu Ohri CFO & Secretary | Aug 11, 2023 | Other | +200,000 | $0.29 | $58.00K | 300,000 |
| Michael Martin Breen Executive Chairman/Interim CEO, Director | Aug 11, 2023 | Award | +200,000 | $0.29 | $58.00K | 856,218 |
| Michael Martin Breen Executive Chairman/Interim CEO, Director | Apr 11, 2023 | Buy | +50,000 | $0.50 | $25.00K | 656,218 |
| Manu Ohri CFO & Secretary | Apr 6, 2023 | Buy | +50,000 | $0.50 | $25.00K | 50,000 |
| Manu Ohri CFO & Secretary | Jul 15, 2022 | Other | +100,000 | – | – | 100,000 |
| Manu Ohri CFO & Secretary | Jul 15, 2022 | Other | −100,000 | – | – | 0 |
| Manu Ohri CFO & Secretary | Jul 15, 2022 | Award | +100,000 | – | – | 100,000 |
| Michael Martin Breen Exec. Chair. and Interim CEO, Director | Jul 15, 2022 | Award | +278,058 | – | – | 606,218 |
| Michael Martin Breen Director | Feb 25, 2021 | Conversion | +40,243 | $3.40 | $136.83K | 318,301 |
| Michael Martin Breen Director | Feb 25, 2021 | Conversion | +9,859 | $3.40 | $33.52K | 328,160 |
| Gregory Berk Director | Feb 16, 2021 | Award | +278,058 | – | – | 278,058 |
| Michael Martin Breen Director | Feb 16, 2021 | Award | +278,058 | – | – | 278,058 |
| Bruce Wendel Director | Feb 16, 2021 | Award | +347,572 | – | – | 352,655 |
| Bruce Wendel Director | Dec 22, 2020 | Buy | +1,374 | $8.87 | $12.19K | 4,642 |
| Bruce Wendel Director | Dec 22, 2020 | Buy | +441 | $8.73 | $3.85K | 5,083 |
| Steven W. Weldon – | Dec 22, 2020 | Sale(10b5-1 plan) | −47,978 | $0.40 | $19.19K | 3,720,000 |
| Steven W. Weldon – | Dec 21, 2020 | Sale(10b5-1 plan) | −35,722 | $0.34 | $12.15K | 3,767,978 |
| Steven W. Weldon – | Dec 21, 2020 | Sale(10b5-1 plan) | −50,000 | $0.30 | $15.00K | 3,853,700 |
| Steven W. Weldon – | Dec 21, 2020 | Sale(10b5-1 plan) | −50,000 | $0.33 | $16.50K | 3,803,700 |
| Steven W. Weldon – | Dec 18, 2020 | Sale(10b5-1 plan) | −50,000 | $0.30 | $15.00K | 3,903,700 |
| Steven W. Weldon – | Dec 17, 2020 | Sale(10b5-1 plan) | −50,000 | $0.31 | $15.50K | 3,953,700 |
| Steven W. Weldon – | Dec 17, 2020 | Sale(10b5-1 plan) | −50,000 | $0.30 | $15.00K | 4,003,700 |
| Steven W. Weldon – | Dec 16, 2020 | Sale(10b5-1 plan) | −50,000 | $0.30 | $15.00K | 4,053,700 |
| Steven W. Weldon – | Dec 15, 2020 | Sale(10b5-1 plan) | −50,000 | $0.30 | $15.00K | 4,153,700 |
| Steven W. Weldon – | Dec 15, 2020 | Sale(10b5-1 plan) | −50,000 | $0.30 | $15.00K | 4,203,700 |
| Steven W. Weldon – | Dec 15, 2020 | Sale(10b5-1 plan) | −50,000 | $0.32 | $16.00K | 4,103,700 |
| Steven W. Weldon – | Dec 14, 2020 | Sale(10b5-1 plan) | −50,000 | $0.28 | $14.00K | 4,350,000 |
| Steven W. Weldon – | Dec 14, 2020 | Sale(10b5-1 plan) | −46,300 | $0.29 | $13.43K | 4,253,700 |
| Steven W. Weldon – | Dec 14, 2020 | Sale(10b5-1 plan) | −50,000 | $0.29 | $14.50K | 4,300,000 |
| Steven W. Weldon – | Dec 11, 2020 | Sale(10b5-1 plan) | −50,000 | $0.25 | $12.50K | 4,450,000 |
| Steven W. Weldon – | Dec 11, 2020 | Sale(10b5-1 plan) | −50,000 | $0.26 | $13.00K | 4,400,000 |
| Bruce Wendel Director | Nov 16, 2020 | Buy | +3,268 | $3.14 | $10.26K | 3,268 |
| Tony Cataldo CEO, Director, 10% owner | Jun 2, 2020 | Sale | −4,234,320 | – | – | 6,500,000 |
| Steven W. Weldon CFO, Director | May 13, 2020 | Sale | −2,269,708 | – | – | 4,500,000 |
| Steven W. Weldon CFO, Director, 10% owner | Aug 14, 2019 | Award | +4,500,000 | – | – | 6,769,707 |
| Tony Cataldo CEO, Director, 10% owner | Aug 14, 2019 | Award | +7,000,000 | – | – | 10,734,320 |
| Tony Cataldo Director | Feb 6, 2019 | Sale | −800,000 | – | – | 4,029,600 |
| Raymond W. Urbanski CEO, Director | Feb 1, 2019 | Sale | −176,980 | – | – | 1,351,918 |
| Tony Cataldo Executive Chairman, Director, 10% owner | Nov 2, 2017 | Gift | −100,000 | – | – | 4,843,029 |
| Tony Cataldo Executive Chairman, Director, 10% owner | Nov 2, 2017 | Gift | −3,000,000 | – | – | 1,843,029 |
| Tony Cataldo Executive Chairman, Director, 10% owner | Nov 2, 2017 | Gift | −200,000 | – | – | 4,943,029 |
| Steven W. Weldon CFO, Director | Sep 1, 2017 | Award | +2,566,835 | – | – | 2,568,840 |
| Tony Cataldo Executive Chairman, Director, 10% owner | Sep 1, 2017 | Award | +5,129,660 | – | – | 5,143,029 |
| Investment Fund Ltd Bristol 10% owner | Apr 5, 2016 | Other | +250,000 | – | – | 463,806 |
| Investment Fund Ltd Bristol 10% owner | Apr 4, 2016 | Sale | −675,000 | $303750.00 | $205.03B | 1,525,472 |
| Theorem Group, LLC 10% owner | Dec 27, 2010 | Sale | −360,100 | $0.13 | $46.81K | 0 |
| Anshuman Dube Director, 10% owner | Dec 27, 2010 | Sale | −360,100 | $0.13 | $46.81K | 0 |
| Theorem Group, LLC 10% owner | Dec 23, 2010 | Sale | −339,900 | $0.13 | $44.19K | 360,100 |
| Theorem Group, LLC 10% owner | Dec 23, 2010 | Conversion | +700,000 | $0.05 | $35.00K | 700,000 |
| Anshuman Dube Director, 10% owner | Dec 23, 2010 | Conversion | +700,000 | $0.05 | $35.00K | 700,000 |
| Anshuman Dube Director, 10% owner | Dec 23, 2010 | Sale | −339,900 | $0.13 | $44.19K | 360,100 |
| Gary M. Post – | Aug 31, 2010 | Sale | −69,600 | $0.11 | $7.66K | 900,000 |
| Gary M. Post – | Aug 30, 2010 | Sale | −30,940 | $0.11 | $3.40K | 969,600 |
| Gary M. Post – | Aug 26, 2010 | Sale | −76,060 | $0.12 | $9.13K | 1,000,540 |
| Gary M. Post Secretary, Director | Jul 8, 2010 | Sale | −50,000 | $0.11 | $5.50K | 1,076,600 |
| Gary M. Post Secretary, Director | Jul 7, 2010 | Sale | −25,000 | $0.11 | $2.75K | 1,375,000 |
| Gary M. Post Secretary, Director | Jul 7, 2010 | Sale | −100,000 | $0.11 | $11.00K | 1,400,000 |
| Gary M. Post Secretary, Director | Jul 7, 2010 | Sale | −33,400 | $0.11 | $3.67K | 1,341,600 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.